Clinical Trials Browser

Phase 2/3 × budigalimab × 1 year × Clear all

NCT06236438 2026-02-23

LIVIGNO-4

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06109272 2025-08-15

LIVIGNO-2

Phase 2/3 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular